-+ 0.00%
-+ 0.00%
-+ 0.00%

Signet Healthcare Partners sells Chr. Olesen Synthesis to Samfara LLP

PUBT·10/02/2026 14:30:41
Listen to the news
Signet Healthcare Partners sells Chr. Olesen Synthesis to Samfara LLP
  • Funds managed by Signet Healthcare Partners, alongside Chr. Olesen, sold Chr. Olesen Synthesis to London-based life sciences investor Samfara.
  • Chr. Olesen Synthesis makes active pharmaceutical ingredients and intermediates, with a focus on controlled substances, from a cGMP plant near Copenhagen.
  • The business supplies pharmaceutical customers across Europe, North America, and the Middle East.
  • Financial terms were not disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Signet Healthcare Partners published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.